Entry

D04603                      Drug

Name

Ipilimumab (USAN/INN);
Ipilimumab (genetical recombination) (JAN);
Yervoy (TN)

Product

YERVOY (E.R. Squibb & Sons)

Formula

C6472H9972N1732O2004S40

Exact mass

145300.0471

Mol weight

145389.4301

Sequence

(Heavy chain)
QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYTMHWVRQA PGKGLEWVTF ISYDGNNKYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAIYYCARTG WLGPFDYWGQ GTLVTVSSAS
TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL
YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS
VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSRDELT
KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ
GNVFSCSVMH EALHNHYTQK SLSLSPGK
(Light chain)
EIVLTQSPGT LSLSPGERAT LSCRASQSVG SSYLAWYQQK PGQAPRLLIY GAFSRATGIP
DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSPWTFG QGTKVEIKRT VAAPSVFIFP
PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL
TLSKADYEKH KVYACEVTHQ GLSSPVTKSF NRGEC
(Disulfide bridge: H22-H96, H145-H201, H221-L215, H227-H'227, H230-H'230, H262-H322, H368-H426, H'22-H'96, H'145-H'201, H'221-L'215, H'262-H'322, H'368-H'426, L23-L89, L135-L195, L'23-L'89, L'135-L'195)

Type

Peptide

Class

Antineoplastic
DG02938 Immune checkpoint inhibitor

Remark

Therapeutic category:

4291

ATC code:

L01FX04

Product:

D04603<JP/US>

Efficacy

Antineoplastic, Immune checkpoint inhibitor, Anti-CTLA4 antibody

Disease

Melanoma [DS:H00038]
Renal cell carcinoma [DS:H00021]
Colorectal cancer (MSI-H or dMMR) [DS:H00021]
Hepatocellular carcinoma [DS:H00048]

Comment

Monoclonal antibody

Target

CTLA4 (CD152) [HSA:1493] [KO:K06538]

Pathway

hsa04660

T cell receptor signaling pathway

Interaction

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FX Other monoclonal antibodies and antibody drug conjugates
     L01FX04 Ipilimumab
      D04603  Ipilimumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Ipilimumab
    D04603  Ipilimumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D04603  Ipilimumab (USAN/INN); Ipilimumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D04603  Ipilimumab
Drug classes [BR:br08332]
Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D04603  Ipilimumab
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
  Other cell surface molecules
   Immune checkpoints
    CTLA4 (CD152)
     D04603  Ipilimumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D04603
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D04603
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
  D04603
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D04603
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
  D04603

Other DBs

CAS:	477202-00-9

PubChem:

47206447